

1

1 **Ignoring transmission dynamics leads to underestimation of the impact of a novel**
2 **intervention against mosquito-borne disease**

3 *Sean M. Cavany**, *John H. Huber**, *Annaliese Wieler*, *Quan Minh Tran*, *Manar Alkuzweny*,

4 *Margaret Elliott*, *Guido España*, *Sean M. Moore*, *T. Alex Perkins*

5 *Department of Biological Sciences and Eck Institute for Global Health, University of Notre Dame*

6 **Contributed Equally*

7 *For correspondence: Sean Cavany (scavany@kolabnow.com), John Huber (jhuber3@nd.edu),*

8 *and Alex Perkins (taperkins@nd.edu).*

9 **Key words:** Mathematical modeling, vector control, dengue, *Wolbachia*, cluster-randomized
10 trials, bias

11 **Abstract**

12 New vector-control technologies to fight mosquito-borne diseases are urgently needed, the
13 adoption of which depends on efficacy estimates from large-scale cluster-randomized trials
14 (CRTs). The release of *Wolbachia*-infected mosquitoes is one promising strategy to curb
15 dengue virus (DENV) transmission, and a recent CRT reported impressive reductions in dengue
16 incidence following the release of these mosquitoes. Such trials can be affected by multiple
17 sources of bias, however. We used mathematical models of DENV transmission during a CRT
18 of *Wolbachia*-infected mosquitoes to explore three such biases: human movement, mosquito
19 movement, and coupled transmission dynamics between trial arms. We show that failure to
20 account for each of these biases would lead to underestimated efficacy, and that the majority of
21 this underestimation is due to a heretofore unrecognized bias caused by transmission coupling.
22 Taken together, our findings suggest that *Wolbachia*-infected mosquitoes could be even more
23 promising than the recent CRT suggested. By emphasizing the importance of accounting for
24 transmission coupling between arms, which requires a mathematical model, our results highlight
25 the key role that models can play in interpreting and extrapolating the results from trials of
26 vector control interventions.

2

3

27 **Competing interests**

28 The authors declare no competing interest.

29 **Funding**

30 This work was funded by the NIH National Institute of General Medical Sciences R35 MIRA
31 program (R35GM143029). John Huber was additionally supported by an NSF Graduate
32 Research Fellowship.

33 **Data availability**

34 All code and other files to reproduce our results is available at:

35 https://github.com/scavany/awed_trial_modeling/

36

37 **Introduction**

38 Dengue virus (DENV) poses a risk to around half the world's population due to the widespread
39 abundance of its *Aedes* mosquito vectors [1]. Historically, the success of dengue control has
40 been limited by challenges such as the expanding distribution of *Aedes aegypti* due to
41 urbanization and land-use changes, and ineffective or sub-optimally applied control strategies
42 [2,3]. One novel control strategy that holds promise is the release of mosquitoes infected with
43 *Wolbachia*, a vertically transmitted intracellular bacteria that reduces the ability of *Aedes aegypti*
44 mosquitoes to transmit DENV [4]. A cluster-randomized, controlled trial conducted between
45 2018 and 2020 in Yogyakarta, Indonesia (Applying Wolbachia to Eliminate Dengue, AWED)
46 [5,6] estimated that release of *Wolbachia*-infected mosquitoes had a protective efficacy against
47 symptomatic, virologically confirmed dengue of 77.1% (95% confidence interval: 65.3-84.9%)
48 [7].

49 There are at least three factors that can result in underestimated efficacy in this type of
50 trial. All operate by making outcomes in treatment and control clusters appear more similar than
51 if these factors were not at play, although they result in this for different reasons. First, the
52 movement of humans between control and treated clusters can increase the exposure to DENV

4

2

5

53 of study subjects residing in treatment clusters and lower the exposure of subjects residing in
54 control clusters [8]. Second, the movement of mosquitoes between arms can lead to an
55 appreciable proportion of mosquitoes in control clusters infected with *Wolbachia*, lowering these
56 mosquitoes' ability to transmit DENV and introducing a source of contamination across trial
57 arms. Third, the dynamic, spatially localized nature of DENV transmission [9,10] implies that
58 suppression of transmission in treated clusters could influence transmission in neighboring
59 control clusters, thereby reducing incidence in both trial arms. Hereafter, we refer to each of
60 these three forms of bias as "human movement," "mosquito movement," and "transmission
61 coupling," respectively.

62 In their per-protocol analyses, Utarini *et al.* [7] acknowledged the potential effects of
63 human and mosquito movement in their per-protocol analysis, and by incorporating recent travel
64 and *Wolbachia* prevalence into their efficacy calculations did not detect a difference in efficacy
65 from that estimated in the intention-to-treat analysis. Nevertheless, the analysis of the AWED
66 trial by Utarini *et al.* [7] did not account for transmission coupling, and they noted that follow-up
67 analyses were needed to further explore the potential for bias due to human and mosquito
68 movement.

69 Understanding the magnitude of such biases is important when seeking to extrapolate
70 the impact of interventions across contexts. Such extrapolation has been recently undertaken for
71 the RTS,S/AS01 vaccine [11,12] and the endectocide ivermectin [13] for malaria. If failing to
72 account for such transmission dynamics contributes to an underestimated biological effect of
73 *Wolbachia* on DENV, we risk incorrectly assessing its broader impact. Given the myriad
74 intervention options available to public health officials for dengue control [14], it is important for
75 the potential impacts of each to be understood as well as possible.

76 In this study, we used a mathematical model of DENV transmission to gain insight into
77 the possible magnitudes of the three aforementioned sources of bias. Our approach involved
78 translating model inputs of the basic reproduction number (R_0), the spatial scale of human


6

3

7

79 movement (b), and the proportional reduction in R_0 afforded by *Wolbachia*-infected mosquitoes
 80 (ε) into outputs of the infection attack rate (IAR) in control and treatment arms of a trial, in
 81 accordance with a seasonal, two-patch susceptible-infectious-recovered (SIR) model [15]. We
 82 used the outputs of IAR in treatment and control arms (IAR_t and IAR_c , respectively) to obtain an
 83 estimate of the odds ratio (OR) of infection and, thereby, an estimate of the efficacy of the
 84 intervention, $Eff = 1 - OR$. We constructed six different model versions for estimating efficacy,
 85 each of which includes different combinations of the three biases, all of them, or none of them.
 86 Henceforth, we refer to the efficacy observed in the AWED trial as “observed efficacy,” and the
 87 efficacy estimated by a given model and ε as “estimated efficacy.” Finally, we quantify each bias
 88 as the difference in the efficacy estimated by a model including that bias and a model which
 89 does not include that bias (see *Methods* for more details of our methods).

90



91

92 **Fig. 1: The spatial scales of transmission and trial design.** A: Idealized trial design. We
 93 used a checkerboard pattern to approximate the design of the AWED trial of *Wolbachia*-infected
 94 mosquitoes to control dengue [7]. ρ_{ij} represents the amount of time an individual who lives in
 95 arm i spends in arm j , where i and j can represent either control (c) or treatment (i). b describes

8

4

9

96 *the scale of human movement. B: The relationship between the scale of human movement and*
97 *the amount of time individuals spend in clusters of the same type as their home cluster. C: The*
98 *relationship between the reduction in R_0 (ϵ) required to reproduce the observed efficacy in the*
99 *AWED trial and the time people spend in their allocated arm. In this panel and panels E and F,*
100 *the dark blue line corresponds to the observed mean estimated in the AWED trial whereas the*
101 *light blue line and shaded region correspond to the 95% confidence intervals. D: The*
102 *relationship between ϵ and the estimated efficacy when $b = 60$ m. The black line shows the*
103 *theoretical relationship between a reduction in R_0 and observed efficacy, assuming no mosquito*
104 *movement and no human movement between arms. The blue line shows this relationship if we*
105 *include these two factors as well as the effect of transmission coupling. The dark and light blue*
106 *squares indicate the mean and the 95% confidence interval respectively of the observed*
107 *efficacy in the AWED trial and the corresponding reduction in R_0 . E: The relationship between*
108 *the amount of time people spend in their allocated arm and the estimated efficacy. F: The*
109 *relationship between the size of the clusters and the estimated efficacy. The dashed line*
110 *indicates the estimated efficacy at the baseline cluster size (1000m). In all panels, parameters*
111 *are at their baseline given in Table S1 unless otherwise stated.*
112

113 **Results**

114 We assumed a checkerboard pattern of control and treatment arms of 1 km² to
115 approximate the design used in the AWED trial, which covered the entire city of Yogyakarta,
116 with neighboring areas assigned to one arm or another in an (approximately) alternating pattern
117 (Fig. 1A) [7], and assume that individuals are evenly distributed within each cluster such that
118 they have no internal spatial structure. The time that humans spend away from their home is
119 assumed to follow a Laplace distribution (Fig. 1A, top right), which takes a single parameter, b ,
120 that we refer to as the scale of human movement. By assuming that individuals are evenly
121 distributed within each cluster, we can then estimate the average proportion of time that
122 individuals in each trial arm spend in their own arm (ρ_{tt} and ρ_{cc}) and in the opposite arm (ρ_{tc} and
123 ρ_{ct} — see the *Apportionment of time at risk* section in *Methods* for details). Larger values of b
124 imply that people spend less time in their allocated arm, and for large values of b individuals
125 spend roughly equal amounts of time in both arms (Fig. 1B).

126 The relationship between the efficacy estimated by the model with all three forms of bias
127 (the estimated efficacy) and the reduction in R_0 (ϵ) was dependent on the amount of time people
128 spent in their allocated arm (Fig. 1C)—the less time individuals spent in their allocated arm, the
129 higher the reduction in R_0 that was needed to recreate the observed efficacy from the AWED

11

130 trial. If individuals spent less than 83.9% of their time in their allocated arm, it was impossible to
131 generate the observed efficacy (77.1%), as that would have implied that ε exceeded 1.
132 Assuming that individuals spent 92.9% of their time in their allocated arm (i.e., $p_{ii} = 92.9\%$,
133 corresponding to $b = 36.9$ m — see the *Spatial Scale of Human Movement* section in *Methods*
134 for details and justification), we found that the observed efficacy (77.1% [95% CI: 65.3% -
135 84.9%]) corresponded to an ε of 49.9% (95% CI: 30.8% - 73.1%) (Fig. 1D, blue line). If we
136 instead assumed that there was no movement between trial arms, we observed that much
137 smaller values of ε were needed to explain the observed efficacy (6.3% [95% CI: 4.8% - 8.1%]).
138 The difference between these estimates provides an indication of the extent of bias introduced
139 by assuming that humans and mosquitoes remain in their allocated arms, when they in fact do
140 not (Fig. 1D).

141 When we fixed ε to the value that reproduces the observed efficacy in the AWED trial
142 and increased human movement between arms by increasing b , the estimated efficacy by the
143 model accounting for all three forms of bias decreased (Fig. 1E). For example, increasing the
144 average distance in one direction between transmission pairs (b) from 36.9 m to 70 m caused a
145 relative reduction of 20.0% in estimated efficacy, highlighting the sensitivity of efficacy to the
146 spatial scale of human movement. This effect occurs for two reasons: first, as people spend less
147 time in their allocated arm, the proportion of time that people spend under the intervention
148 becomes more similar between arms; and secondly, in the presence of transmission coupling, a
149 reduction in prevalence in the intervention arm reduces transmission in the control arm more as
150 people spend less time in their allocated arm. Relatedly, estimated efficacy depended on the
151 dimensions of the trial clusters, which we set to 1 km² by default (Fig. 1F). When we reduced
152 the cluster dimensions to 500 m x 500 m, estimated efficacy dropped from 77.1% to 60.3%,
153 representing a 21.8% relative reduction. This effect occurs because, as the cluster dimensions
154 are reduced, people spend less time in their home cluster. Hence, the time spent in each trial
155 arm approaches parity (i.e., 50%). Increasing cluster dimensions above 1 km² had somewhat

12


6

13

156 less of an effect on estimated efficacy. For example, increasing the cluster dimensions to 2 km x
157 2 km resulted in an estimated efficacy of 86.7%, a relative increase of 12.4%.

158 Our approach enabled us to directly and separately model each of the three potential
159 sources of bias: (1) mosquito movement, (2) human movement, and (3) transmission coupling.
160 Movement of *Wolbachia*-infected mosquitoes is modeled by including a time-varying level of
161 coverage, and we assume that mosquito movement does not contribute to DENV transmission
162 (See *Methods - wMel coverage*). When we assumed that ϵ was equal to 49.9%, allowing for
163 mosquito movement but not human movement produced an estimated efficacy of 99.1%,
164 because there was almost no transmission in the intervention arm in that case (Fig. 2A, Fig.
165 S7). If we allowed for both mosquito movement and human movement, we observed a lower
166 estimated efficacy of 93.6%. Although there was little transmission in the intervention arm in this
167 case, individuals residing in the intervention arm could be infected in the control arm.
168 Additionally, those assigned to the control arm experienced lower overall risk due to their time
169 spent in the intervention arm. When we accounted for transmission coupling between trial arms
170 alongside human and mosquito movement, thereby allowing for more transmission in the
171 intervention arm, risk was the most similar across the trial arms of all scenarios, leading to the
172 lowest estimated efficacy of 77.1% for an ϵ equal to 49.9%.

15



173

174 **Fig. 2: Sources of bias in efficacy estimates.** In both panels, yellow refers to mosquito
 175 movement, red to human movement, and blue to transmission coupling. A: The relationship
 176 between the reduction in R_0 (ϵ) and the estimated efficacy for the six possible models. The black
 177 line here is the relationship for a model with no human movement or mosquito movement.
 178 Where a line has more than one color, it represents the model which includes each of the types
 179 of bias represented by those colors. The difference between this line and each of the colored
 180 lines represents the bias introduced by not accounting for the features present in the model
 181 described by that colored line. B: the contribution of each source of bias to the total bias. $Eff^{(0)}$
 182 refers to the estimated efficacy from a model with none of the biases, $Eff^{(h)}$ to the estimated
 183 efficacy from a model with human movement only, $Eff^{(m)}$ to the estimated efficacy from a model
 184 with mosquito movement only, $Eff^{(hm)}$ to the estimated efficacy from a model with human and
 185 mosquito movement, $Eff^{(ht)}$ to the estimated efficacy from a model with human movement and
 186 transmission coupling, and $Eff^{(hmt)}$ to the estimated efficacy from a model with all three biases.
 187

188 We quantified total bias as $Eff^{(hmt)} - Eff^{(0)}$, where $Eff^{(hmt)}$ is the estimated efficacy under the
 189 model with all sources of bias and $Eff^{(0)}$ is the estimated efficacy under the model without human
 190 or mosquito movement. We then computed the difference in the bias produced by pairs of

16

8

17

191 models to decompose overall bias into each of its three sources (Fig. 2B, Fig. S8-9, see
192 *Methods* for details). At the baseline ϵ of 49.9%, 17.6% of the total bias was attributable to
193 mosquito movement, 8.3% to human movement, and 74.1% to transmission coupling. At all
194 values of ϵ , the greatest source of bias was transmission coupling between trial arms. When ϵ
195 was below a value of around 10%, the effective reproduction number at the start of the trial
196 exceeded 1 in both arms. This value of ϵ varied slightly based on the model used (Fig. S8-9). If
197 ϵ was below this critical value, increasing it in the context of coupled transmission reduced
198 incidence in the control arm and caused smaller reductions in incidence in the intervention arm
199 than if transmission had been uncoupled (Fig. S7, e.g. panels D vs. F). This implies that the bias
200 introduced by transmission coupling increases as ϵ increases up to ~10% under our model's
201 parameterization (Fig. 2B). Increasing ϵ past this point only leads to small reductions in
202 incidence in the intervention arm in an uncoupled model, as incidence is already very low.

203

204 **Discussion**

205 Our results highlight three sources of bias (human movement, mosquito movement, and
206 transmission coupling) that arise in large, cluster-randomized, controlled trials of interventions
207 against mosquito-borne diseases, and have implications for how to mitigate these biases.
208 Biases arising due to human movement and mosquito movement are typically able to be
209 addressed through careful statistical analysis of trial data or in the design of the trial [8]. For
210 instance, in the per-protocol analysis of the AWED trial, Utarini *et al.* accounted for these two
211 forms of bias by combining self-reported recent travel and local *Wolbachia* prevalence into an
212 individual-level *Wolbachia* exposure index [7]. Comparing groups with the highest and lowest
213 *Wolbachia* exposure did not lead to higher efficacy estimates than their primary analysis.
214 Another approach to addressing contamination involves describing the effectiveness of the
215 intervention at the boundary between clusters using a sigmoid function [16–18]. Our results
216 suggest that failure to take steps such as this to account for human and mosquito movement

18

19

217 would typically lead to underestimated efficacy, while failure to account for transmission
218 coupling would lead to an even greater underestimate, particularly at intermediate reductions in
219 R_0 .

220 Bias arising from human and mosquito movement could also be mitigated at the stage of
221 planning the trial. The classical design to achieve this is the ‘fried-egg’ design, in which a treated
222 buffer-zone is placed between intervention and control clusters [19]. A more recently proposed
223 approach involves excluding a subset of clusters from the trial completely, thereby increasing
224 the distance between clusters and leading to disconnected clusters at less risk of contamination
225 [20]. While both of these approaches do mitigate the risk of contamination directly, they also
226 necessitate a larger trial area and may be logistically infeasible in a trial taking place in a single
227 city, as was the case for the AWED trial. Another approach could include reducing the number
228 of clusters, but keeping the total area fixed, leading individuals to spend more time in their
229 assigned arm and reducing mosquito movement by reducing the boundary between clusters.
230 Our results show that the efficacy estimated from cluster-randomized, controlled trials of
231 interventions against mosquito-borne diseases is highly sensitive to cluster size (Fig. 1F). Had
232 the dimensions of the clusters in the AWED trial been much smaller, then the estimated efficacy
233 may have been substantially lower. However, having fewer, yet larger clusters would likely
234 introduce new biases by making the arms less comparable, which may not be an acceptable
235 trade-off.

236 While bias due to human and mosquito movement can be mitigated through trial design
237 and statistical methods, our results highlight a third source of bias, transmission coupling, that
238 requires additional tools to fully address. Accounting for this bias first requires data on the
239 spatial distribution of the intervention and on human movement, similar to that used in the
240 supplementary analysis of the AWED trial. However, it also requires interfacing these data with
241 a dynamical transmission model to account for the fact that, in the presence of movement
242 between arms, incidence in each arm depends on prevalence in both arms [21]. Many common

20

10

21

243 trial designs will lead to reduced bias due to transmission coupling — for instance by allocating
244 a greater proportion of the trial area to the control arm, with small intervention clusters situated
245 among larger control clusters so that transmission suppression in the intervention arm has less
246 of a population-level effect. The ratio of area allotted to treatment and control would depend on
247 many factors, including the expected strength of the intervention, the local force of infection, and
248 logistical constraints such as the size and length of the trial. Utilizing a dynamical model
249 synthesizing these factors in the design of a trial could aid in understanding how different
250 designs might affect bias due to transmission coupling [21]. More work is needed to understand
251 what types of spatial clustering patterns, among other features of trial design, would minimize
252 this form of bias.

253 Although our modeling approach allowed us to account for different potential sources of
254 bias and to attribute the total bias to each of those sources, it has at least four limitations. First,
255 our model was deterministic, yet stochasticity could be important for a highly efficacious
256 intervention with potential to reduce transmission to very low levels [22]. This simplification
257 implies that our estimates are likely conservative, as these effects could increase the bias due
258 to transmission coupling if a highly effective intervention increases the probability of
259 transmission fadeouts. Second, our simple model does not reflect all of the complexities of
260 DENV transmission. For example, we did not account for spatial heterogeneities in transmission
261 or interactions between serotypes. Accurately quantifying the contribution of these effects to
262 bias would require a more detailed model, but the qualitative results would likely be similar.
263 Third, we did not calibrate our model to trial data, so incidence in our model may not reflect the
264 actual incidence during the trial. However, our aim here was not to precisely quantify bias in the
265 AWED trial, but rather to highlight some potential sources of bias in trials of that nature and to
266 understand how these biases are influenced by transmission dynamics and human mobility.
267 Moreover, our model was calibrated to actual incidence from past years in Yogyakarta, and so
268 still reflects transmission typical of that location. It is also worth noting that an earlier version of

22

23

269 the manuscript, which used a simpler static model based on epidemic attack rate formulae, had
270 qualitatively similar findings [23]. Finally, we don't account for heterogeneity between clusters,
271 such as regions of the city with systematically higher mosquito abundance, or greater human
272 movement, or within clusters, such as that transmission may be higher at the edge of control
273 clusters.

274 In conclusion, without accounting for human movement, mosquito movement, and
275 transmission coupling, the efficacy of *Wolbachia*-infected mosquitoes as an intervention to
276 control dengue is likely to be underestimated. As the estimate of efficacy in the AWED trial was
277 already very high (77.1% [95% CI: 65.3% - 84.9%]) [7] and, as we show, likely underestimated,
278 *Wolbachia*-infected mosquitoes have potential to be a game-changing tool in the fight against
279 dengue. Even as vaccines against dengue become available, a variety of vector control
280 approaches are likely to remain key tools in the fight against dengue [2,14]. Although we
281 focused our study on a trial of *Wolbachia*-infected mosquitoes, our findings are applicable to any
282 efficacy trial of an intervention that has the potential to contaminate the control arm, such as
283 gene drive mosquitoes or ivermectin as interventions against malaria [24,25]. As trials of these
284 interventions continue, it will be important to learn what lessons we can from transmission
285 dynamic modeling when designing and interpreting future trials to ensure that we understand
286 the true promise of these interventions.

287

288 **Methods**

289 **Transmission model**

290 We simulated DENV transmission using a four-serotype, two-patch seasonal SIR model. In this
291 model, fully susceptible individuals may become infected with any of the four serotypes. Once
292 infected, individuals have an exponentially-distributed period of cross-immunity to all other
293 serotypes with a mean of two years. Individuals with prior exposure to one or more serotypes
294 but that are not currently in their period of cross-immunity are immune to the serotypes they

24

12

25

295 have previously been infected with. We implicitly assume that all four serotypes circulate in
296 equal proportions. Births and deaths are modeled so that the population size remains constant,
297 and the mortality rate is the reciprocal of the mean life expectancy, taken from the United
298 Nations World Population Prospects database [26]. The transmission parameter, $\beta(t)$, varies
299 seasonally according to a sine curve with a period equal to one year. The model equations are
300 as follows, with parameter definitions and values given in Tables S1 and S2, and the model
301 diagram is shown in Fig. S1.

302
$$\frac{dS_0}{dt} = \mu(1 - S_0) - P \times (1 - \epsilon C(t)) \beta(t) \frac{I}{N} S_0$$

303
$$\frac{dI_1}{dt} = P \times (1 - \epsilon C(t)) \beta(t) \frac{I}{N} S_0 - (\gamma + \mu) I_1$$

304
$$\frac{dR_1}{dt} = \gamma I_1 - (\omega + \mu) R_1$$

305
$$\frac{dS_1}{dt} = \omega R_1 - P \times (1 - \epsilon C(t)) \beta(t) \frac{3}{4} \frac{I}{N} S_1 - \mu S_1$$

306
$$\frac{dI_2}{dt} = P \times (1 - \epsilon C(t)) \beta(t) \frac{3}{4} \frac{I}{N} S_1 - (\gamma + \mu) I_2$$

307
$$\frac{dR_2}{dt} = \gamma I_2 - (\omega + \mu) R_2$$

308
$$\frac{dS_2}{dt} = \omega R_2 - P \times (1 - \epsilon C(t)) \beta(t) \frac{1}{2} \frac{I}{N} S_2 - \mu S_2$$

309
$$\frac{dI_3}{dt} = P \times (1 - \epsilon C(t)) \beta(t) \frac{1}{2} \frac{I}{N} S_2 - (\gamma + \mu) I_3$$

310
$$\frac{dR_3}{dt} = \gamma I_3 - (\omega + \mu) R_3$$

311
$$\frac{dS_3}{dt} = \omega R_3 - P \times (1 - \epsilon C(t)) \beta(t) \frac{1}{4} \frac{I}{N} S_3 - \mu S_3$$

312
$$\frac{dI_4}{dt} = P \times (1 - \epsilon C(t)) \beta(t) \frac{1}{4} \frac{I}{N} S_3 - (\gamma + \mu) I_4$$

26

13

27

313
$$\frac{dR_4}{dt} = \gamma I_4 - \mu R_4$$

314
$$I = I_1 + I_2 + I_3 + I_4$$

315
$$\beta(t) = \beta_0 \left(1 + \beta_a \sin\left(\frac{2\pi(\theta+t)}{365.25}\right) \right) \quad (S1)$$

316

317 **Table S1.** Model parameter values

Symbol	Definition	Value	Source
μ	Mortality rate (day ⁻¹)	1/(71.4 x 365.25)	UN World Population Database [26]
ϵ	Transmission reduction due to <i>Wolbachia</i>	<i>varied</i>	N/a
P	A 2x2 matrix describing the proportion of time people spend in their home and non-home patches	<i>varied</i>	See Model parameterization section
$C(t)$	A 1x2 vector describing the time-varying coverage of <i>Wolbachia</i> in each patch	See Fig. S6	Utarini et al. [7]
γ	Recovery rate (day ⁻¹)	1/7	Burattini et al. [27]
ω	Waning rate of cross-immunity (day ⁻¹)	1/(2 x 365.25)	Reich et al. [28]
R_0	Basic reproduction number	3.21	See Model parameterization section
α	Amplitude in rate of effective contact	<i>calibrated</i> bounds: (0, 0.2) estimate: 0.0588	N/a
θ	Offset in seasonality (days)	<i>calibrated</i> bounds: (0, 180) estimate: 77.8	N/a
ν	Proportion of infections reported as cases	<i>calibrated</i> bounds: (0.01, 0.2) estimate: 0.0601	N/a


318

319 **Table S2.** All state variables are 1x2 vectors describing the number in each of the two patches.

29

Symbol	Definition
S_i	Number of susceptible individuals with i prior infections
I_i	Number of infectious individuals with i prior infections
R_i	Number of immune individuals with i prior infections; individuals in this group are immune to all serotypes until their cross-immunity wanes

320



321

322 *Fig. S1: Model diagram. The superscripts refer to the number of times individuals in that*
323 *compartment have been infected. Susceptible individuals (S_i) experience a reduced force of*
324 *infection according to the number of prior infections they have experienced. We assume all*
325 *serotypes circulate equally. Following infection, individuals experience a temporary period of*
326 *immunity to all serotypes (R_i). Mortality occurs at an equal rate from all compartments and is not*

30

15

31

327 shown.

328 Transmission model calibration

329 We calibrated the model to data on reported cases of dengue fever over a ten year period [29]

330 (Fig. S2). We first averaged the monthly number of reported cases, to capture the average

331 dynamics across the period. We ran the model for 100 years to reduce the influence of initial


332 conditions, and then fitted model years 101-110 to the 10 average years from the data using

333 maximum likelihood. We used a Poisson likelihood function,

$$334 \quad L(x_{model}, v | x_{data}) = \frac{(x_{model} v)^{x_{data}} e^{-x_{model} v}}{x_{data}!}, \quad (S2)$$

335 where x_{model} is the number of infections per month predicted by the model and x_{data} is the number

336 of cases per month in the data.



337

338 **Fig. S2: Model calibration.** Calibration of seasonal SIR model to data on dengue cases from

339 Yogyakarta. The faint red line and points show the data on the monthly number of cases from

340 2006 to 2017 in Yogyakarta, taken from Indriani et al. [29]. The solid red lines and points show

341 this data average by month. The gray polygon shows the model calibrated to the average

342 number of monthly cases.

32

16

33

343

344 **Efficacy models**

345 Let ε represent the effectiveness of the intervention, defined as the proportional reduction in the
346 pre-intervention basic reproduction number, R_0 , when the intervention is applied at full coverage
347 in a treatment cluster. Hence, in the absence of human or mosquito movement,

348

$$349 \quad R_{0,t} = (1 - \varepsilon) R_0 \quad (\text{S3})$$

$$350 \quad R_{0,c} = R_0. \quad (\text{S4})$$

351

352 Our interest is in quantifying the infection attack rate (IAR), π , within each cluster during a trial.
353 To do this, we simulate the model for two years, and calculate the infection attack rate in each
354 arm during that time. We estimate the initial proportion in each compartment by first simulating
355 the model for 100 years. We do this with six different models that include combinations of three
356 different types of bias: human movement between arms, mosquito movement between arms,
357 and transmission coupling between arms. The six resulting models are described below (note
358 that transmission coupling can only occur in the presence of human movement). Each model is
359 defined by different values for P and $C(t)$.

360

361 **1. No bias**

362 In the absence of contamination from human movement or mosquito movement between arms,
363 we can essentially use equations (S3) and (S4) to describe the reproduction in each arm. This
364 amounts to setting $C(t) = (1, 0)$ and $P = I$, the identity matrix.

365

366 **2. Bias from mosquito movement**

367 We represent the coverage of the intervention—i.e., the proportion of *Wolbachia*-infected

35

368 mosquitoes—in the two arms with $C_t(t)$ and $C_c(t)$. In the case of mosquito movement, there may
369 be non-zero coverage of intervention in the control arm (i.e., $C_c > 0$), and less than 100%
370 coverage in the treatment arm (i.e., $C_t < 1$). Hence we set $C(t) = (C_c(t), C_t(t))$ and $P = I$.

371 Here we are assuming that movement of mosquitoes between trial arms does not
372 directly contribute to DENV transmission via movement of DENV-infected mosquitoes. This
373 discrepancy can be reconciled by the fact that the spread of dengue virus occurs within a single
374 mosquito generation, whereas the spread of *Wolbachia* occurs over the course of multiple
375 generations.

376

377 **3. Bias from human movement**

378 Let q_{ij} represent the ij^{th} element of P ,—i.e., the proportion of the total time at risk that a resident
379 of cluster i spends in cluster j . To account for human movement, but no transmission coupling,
380 we set $C(t) = (q_{ct}, q_{tt})$ and $P = I$. This is because in this scenario, the wMel coverage in the
381 treatment arm is 1, and in the control arm is 0, so the experienced wMel exposure reduces to
382 the time spent in the treatment arm.

383

384 **4. Bias from human movement and mosquito movement**

385 We now have both human and mosquito movement, so we set

386 $C(t) = (q_{cc}C_c(t) + q_{ct}C_t(t), q_{tc}C_c(t) + q_{tt}C_t(t))$, and $P = I$. Note that, by definition, $q_{tt} + q_{tc} = 1$ and $q_{cc} +$
387 $q_{ct} = 1$.

388

389 **5. Bias from human movement and transmission coupling**

390 Thus far, we have assumed that transmission in each arm is only a function of prevalence in
391 that arm, and not in the other. To relax this assumption, we couple transmission between the
392 two arms by varying P . In the presence of human movement but not mosquito movement, we
393 set $C = (0, 1)$ and $P = (q_{cc}, q_{ct}; q_{tc}, q_{tt})$.

36

18

37

394

395 **6. Bias from human movement, mosquito movement, and transmission coupling**

396 Finally, we include all three forms of bias by again setting $P = (Q_{cc}, Q_{ct}, Q_{tc}, Q_{tt})$, and

397 $C = (C_c(t), C_t(t))$.

398

399 **Efficacy calculation**

400 The ratio of the IARs in the treatment and control clusters is an infection risk ratio. However, the
401 AWED trial based their efficacy calculations upon an odds ratio [7], with symptomatic,

402 virologically-confirmed dengue as the end point. That is, efficacy in the trial was computed as 1-

403 $p_i n_c / p_c n_i$, where p_i and n_i represent enrolled test-positives and test-negatives, respectively, in trial

404 arm i . To generate a comparable quantity, we computed the efficacy according to model x as

405

$$406 \quad Efficacy^{(x)} = 1 - \frac{\pi_t^{(x)} (1 - \pi_c^{(x)})}{\pi_c^{(x)} (1 - \pi_t^{(x)})}, \quad (S5)$$

407

408 where $\pi_i^{(x)}$ is the infection attack rate in trial arm $i \in \{c, t\}$ for model $x \in \{0, h, m, hm, ht, hmt\}$. Here,

409 we are assuming that the ratio of infections to enrolled test-positives does not differ between

410 arms (i.e., $p_i = k_p \pi_i$ for $i \in \{c, t\}$) and similarly the ratio of those uninfected to enrolled test-negatives

411 also does not differ between arms (i.e., $n_i = k_n (1 - \pi_i)$ for $i \in \{c, t\}$). If either of these assumptions

412 were violated, for instance if the intervention affected either the proportion of dengue infections

413 that were symptomatic, then our estimate of efficacy would be less comparable to the estimate

414 used in the AWED trial.

415

416 **Bias calculation**

417 We calculated the bias due to a particular source as the difference in the efficacy between a

418 model with that source of bias and a model without that source of bias. As biases appear in

38

19

39

419 multiple models, this led to three ways to embed the models, and three corresponding ways to
420 quantify each bias. The three embeddings are: A) no bias \rightarrow mosquito movement \rightarrow human
421 movement + mosquito movement \rightarrow full model; B) no bias \rightarrow human movement \rightarrow human
422 movement + mosquito movement \rightarrow full model; and C) no bias \rightarrow human movement \rightarrow human
423 movement + transmission coupling \rightarrow full model. The difference between efficacy estimates for
424 adjacent models in an embedding will lead to an expression for the bias which differs between
425 the two models. Hence, the three possible ways to calculate each of the three sources of bias
426 yields

427

$$428 \quad bias_A^{(m)} = E f f^{(m)} - E f f^{(0)} \quad (S6A)$$

$$429 \quad bias_B^{(m)} = E f f^{(hm)} - E f f^{(h)} \quad (S6B)$$

$$430 \quad bias_C^{(m)} = E f f^{(hmt)} - E f f^{(ht)} \quad (S6C)$$

$$431 \quad bias_A^{(h)} = E f f^{(hm)} - E f f^{(m)} \quad (S7A)$$

$$432 \quad bias_B^{(h)} = E f f^{(h)} - E f f^{(0)} \quad (S7B)$$

$$433 \quad bias_C^{(h)} = E f f^{(h)} - E f f^{(0)} \quad (S7C)$$

$$434 \quad bias_A^{(t)} = E f f^{(hmt)} - E f f^{(hm)} \quad (S8A)$$

$$435 \quad bias_B^{(t)} = E f f^{(hmt)} - E f f^{(hm)} \quad (S8B)$$

$$436 \quad bias_C^{(t)} = E f f^{(ht)} - E f f^{(h)}. \quad (S8C)$$

437

438 We then calculate the average total bias caused by each source of bias as

$$439 \quad bias^{(i)} = \frac{\sum_{j \in \{A, B, C\}} bias_j^{(i)}}{3}, \quad (S9)$$

440

441 where $i \in \{h, m, t\}$. Note that $bias_A^{(t)} = bias_B^{(t)}$ and $bias_B^{(h)} = bias_C^{(h)}$, but it is necessary to include each

40

20

41

442 as a separate term so that each of the three model embeddings is included equally.

443

444 **Model Parameterization**

445 ***Apportionment of Time at Risk***

446 We considered a checkerboard arrangement for the treatment and control clusters in a trial
447 across a two-dimensional landscape (Fig. 1A, Fig. S10). Under this scenario, we assume that
448 the population density per unit area is constant and that transmission potential, as captured by
449 R_0 , is homogeneous across the landscape prior to initiation of the trial.

450 At the core of this derivation is the assumption that the location where an individual j
451 resides who was infected by an individual i is determined by an isotropic transmission kernel,
452 $k(|x_i - x_j|, |y_i - y_j|)$, where x and y are the spatial coordinates for the residence of each of i and
453 j . We use a Laplace distribution with marginal density functions for each of the x and y
454 coordinates,

455

$$456 \quad k(x_j | \mu = x_i, b) = \frac{1}{2b} e^{-\frac{|x_j - \mu|}{b}} \quad (\text{S10})$$

$$457 \quad k(y_j | \mu = y_i, b) = \frac{1}{2b} e^{-\frac{|y_j - \mu|}{b}}. \quad (\text{S11})$$

458

459 where μ is the location parameter and b is the scale parameter [30]. The scale parameter b is
460 equal to the average distance in one direction between the locations where infector and infectee
461 reside.

462 Under the checkerboard arrangement, we considered alternating squares of width δ
463 corresponding to treatment and control clusters within a contiguous urban area (Fig. 1A).
464 Although any such area would have borders in reality, we ignored any possible edges effects
465 and assumed that the extent of interactions between squares of type t and c in the interior of the

42

43

466 checkerboard provide a suitable characterization of overall interaction between individuals
467 residing in t and c , as summarized by ρ_{tt} and ρ_{cc} . Because the area and arrangement of t and c
468 squares are identical, $\rho_{tt} = \rho_{cc}$ and $\rho_{tc} = \rho_{ct}$ (Fig. 1A).

469 We approach this problem by first calculating the proportion of time at risk that an
470 individual i residing on a line within in an interval of width $\delta = \mu_r - \mu_l$ experiences in an adjacent
471 interval of width Δ . Let the former interval span $[\mu_l, \mu_r]$ and the latter interval span $[\mu_r, \mu_r + \Delta]$. If i
472 resides specifically at μ , then the proportion of its time at risk in the other interval is

473

$$474 \quad F(\mu_r + \Delta | \mu, b) - F(\mu_r | \mu, b). \quad (\text{S12})$$

475

476 where $F(\cdot)$ is the Laplace distribution function. To average across all individuals i , we can
477 integrate according to

478

$$479 \quad A_{\delta, \Delta} = \frac{1}{\delta} \int_{\mu_l}^{\mu_r} (F(\mu_r + \Delta | \mu, b) - F(\mu_r | \mu, b)) d\mu. \quad (\text{S13})$$

480

481 which gives the proportion of time in the interval of length Δ for an individual who resides in the
482 interval of length δ . Given that the Laplace distribution function is $F(x | \mu, b) = 1 - \frac{1}{2} \exp(-(x - \mu)/b)$
483 when $x > \mu$, eqn. (S25) evaluates to

484

$$485 \quad A_{\delta, \Delta} = \frac{b}{2\delta} (1 - e^{-\delta/b} - e^{-\Delta/b} + e^{-(\delta + \Delta)/b}). \quad (\text{S26})$$

486

487 We can quantify the proportion of time at risk in the interval of width δ for individuals who reside
488 there as

489

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

45

$$A_{\delta} = 1 - 2 \lim_{\Delta \rightarrow \infty} A_{\delta, \Delta} = 1 - \frac{b}{\delta} (1 - e^{-\delta/b}). \quad (\text{S14})$$

491

492 We also need to calculate the time at risk in a non-adjacent interval of width δ_3 whose edge is
 493 spaced distance δ_2 away from the nearest edge of the interval where the individual resides,
 494 which has width δ_1 . Applying similar reasoning as in eq. (S25), we obtain

495

$$A_{\delta_1, \delta_2, \delta_3} = \frac{b}{2\delta_1} (e^{-\delta_2/b} - e^{-(\delta_1+\delta_2)/b} - e^{-(\delta_2+\delta_3)/b} + e^{-(\delta_1+\delta_2+\delta_3)/b}). \quad (\text{S15})$$

497

498 We can calculate the proportion of time spent in like squares by applying the probabilities used
 499 to calculate the proportions of time at risk for residents who live under treatment or not. Going
 500 out three layers from a focal square (Fig. S10), the proportion of time spent in like squares is

501

$$B = A_{\delta}^2 + 4 A_{\delta, \delta}^2 + 4 A_{\delta, \delta, \delta} A_{\delta} + 4 A_{\delta, \delta, \delta}^2 + 8 A_{\delta, 2\delta, \delta} A_{\delta, \delta} + 4 A_{\delta, 2\delta, \delta}^2, \quad (\text{S16})$$

503

504 and the proportion of time spent in unlike squares is

505

$$C = 4 A_{\delta, \delta} A_{\delta} + 8 A_{\delta, \delta, \delta} A_{\delta, \delta} + 4 A_{\delta, 2\delta, \delta} A_{\delta} + 8 A_{\delta, 2\delta, \delta} A_{\delta, \delta, \delta}. \quad (\text{S17})$$

507

508 The total proportion of time under treatment or not is then

509

$$\rho_{cc} = \rho_{tt} = \frac{B}{B+C} \quad (\text{S18})$$

$$\rho_{tc} = \rho_{ct} = \frac{C}{B+C}. \quad (\text{S19})$$

512

47

513 Hence, for a checkerboard arrangement of clusters, the proportion of time which each individual
514 spends in each arm of the trial is uniquely determined by the width of each cluster (δ) and the
515 scale of human movement (b).

516

517 **Calculation of Initial Susceptibility, force of infection, and R_0**

518 To obtain an estimate of initial susceptibility, we followed ten Bosch *et al.* [31] and calculated the
519 proportion of the population exposed to n serotypes, $\forall n \in \{0,1,2,3,4\}$, as a function of age.

520 Following ten Bosch *et al.* [31], we defined $e_i(a)$ as the proportion of individuals of age a that

521 have been exposed to i serotypes and $r_i(a)$ as the proportion of individuals of age a experiencing

522 temporary heterologous immunity following exposure to i serotypes. The dynamics of how

523 individuals progress through these classes as they age follows

524

$$525 \quad \frac{d e_0}{d a} = -4 \Lambda e_0 \quad (S20)$$

$$526 \quad \frac{d r_i}{d a}_{i=1,\dots,4} = (4 - (i - 1)) \Lambda e_{(i-1)} - \sigma r_i \quad (S21)$$

$$527 \quad \frac{d e_i}{d a}_{i=1,\dots,4} = \sigma r_i - (4 - i) \Lambda e_i. \quad (S22)$$

528

529 In eqs. (S33-S35), $\Lambda = 0.0457$ is the force of infection, and σ is the rate at which individuals lose
530 heterologous immunity, which we set to 0.5/yr [31].

531 We computed the proportion of the population in Yogyakarta, Indonesia that is of age a

532 using estimates from the United Nations World Population Prospects database [32] and

533 computed the proportion of the population that is susceptible to their $(i+1)$ th infection as

534

$$535 \quad E_i = \sum_a (p(a) e_i(a)). \quad (S23)$$

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

49

536

537 It follows that initial susceptibility is equal to

538

539
$$S' = E_0 + \frac{3}{4}E_1 + \frac{1}{2}E_2 + \frac{1}{4}E_3, \quad (\text{S24})$$

540


541 provided that the force of infection for each serotype has been constant over time. For the

542 assumed values of Λ and σ , $S' = 0.341$ for Yogyakarta, Indonesia.

543 We used data on seropositivity by age from Yogyakarta [29] to estimate the mean

544 annual force of infection using the above catalytic model (Fig. S3). This led to an estimate of the

545 mean annual per-serotype force of infection of 0.0457.



546

547 **Fig. S3: Force of infection estimation.** The circles show the proportion of individuals that are
548 seropositive by age group in Yogyakarta, and the thin vertical lines show the 95% binomial
549 confidence intervals, both from Indriani et al. [29]. The thick black line shows the proportion that
550 would be expected to be seropositive according to the catalytic model with a per-serotype force
551 of infection of 0.0457.

552

To estimate R_0 from Λ and S' , we use the formula:

53


553
$$R_0 = \frac{\log(S_f) - \log(S')}{S_f - S'}, \quad (\text{S25})$$

554 where S_f is the proportion susceptible after an outbreak. Here we estimate R_0 based on one
555 season's transmission, i.e., $S_f = S' \exp(-4 \Lambda)$, yielding $R_0 = 3.21$. We incorporate this estimate
556 of R_0 into the transmission model by assuming that the mean value of $\beta(t)$ (i.e. β_0) is related to
557 R_0 by $\beta_0 = R_0 \gamma$, i.e. we assume that R_0 represents the number of secondary infections in a fully
558 susceptible population in the absence of seasonality. It is likely that this leads to an
559 overestimate of β_0 , though our model still accurately recreates the typical epidemic peaks and
560 troughs of Yogyakarta (Fig. S2).

561

562 ***Spatial Scale of Human Movement***

563 Our calculations of the apportionment of time at risk depend upon a value of b , the spatial scale
564 of human movement, a quantity that is challenging to parameterize. To do this, we first estimate
565 the relative risk (RR) of 100% wMel coverage compared to 0% wMel coverage, based on the
566 per-protocol analysis in Utarini *et al.* In that analysis, the authors estimated a weighted wMel
567 exposure level based on human movement diaries and local wMel frequency over time. This is
568 essentially the product of the wMel frequency in a location and the amount of time an individual
569 spent there, and then summed over all of the locations at which that individual spent time. They
570 then binned individuals into five equal width groups based on their exposure index and
571 calculated the RR of infection compared to the lowest exposure group (Fig. S4). To estimate the
572 RR of 100% exposure compared to 0%, we fit a logistic curve to the binned RR values (using
573 the midpoints of each bin) and calculate the RR of 100% compared to 0%. This yields a RR of
574 0.18, or equivalently an efficacy of 82%.



575

576 **Fig. S4. Efficacy adjusted for human movement.** Circles and associated confidence intervals

577 show the relative risk at different levels of the wMel exposure index compared to the [0, 0.2)

578 group, according to the per-protocol analysis in Utarini et al. [7]. The horizontal red lines show

579 the relative risk from the intention-to-treat analysis in the same paper. The dashed horizontal


580 indicates a relative risk of 1. The black line indicates a logistic curve fit to the estimates of

581 relative risk from the per-protocol analysis.

582

57

583 To inform our selection of b , we compared the model with all of the biases included to
584 the one with only human movement and transmission coupling. We then selected a value of b
585 which enabled us to select a single value of ε that would lead to 77% efficacy in the full model,
586 and 82% efficacy in the model with human movement and transmission coupling (Fig. S5). This
587 yielded a value of $b=36.9m$, corresponding to $\rho_{tt}=\rho_{cc}=0.929$ and $\rho_{tc}=\rho_{ct}=0.071$ for the
588 checkerboard arrangement.



589

58

29

59

590 **Fig. S5: Estimation of scale of human movement.**

591

592 **wMel coverage**

593 When modeling mosquito movement between trial arms, we use data on the time-varying wMel


594 coverage in each trial arm from the AWED trial [7]. We average across clusters within each arm

595 to find the average coverage over time. As we don't explicitly model mosquitoes or their

596 movement, these averaged time series are then used directly in the model. They are shown in

597 Fig. S6 and are represented in the model by $C(t) = (C_c(t), C_i(t))$, where $C_c(t)$ is given in the left

598 panel and $C_i(t)$ in the right. When mosquito movement is not modeled, $C(t) = (0, 1)$, for all t .



599

600 **Fig. S6. wMel frequency in the AWED trial [7].** Each thin gray line shows the wMel frequency

601 over time in one of the treatment (A) or control (B) clusters. The red line and points show the

602 average of these, which is what was used in the model.

603

61

604 References

- 605 1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global
606 distribution and burden of dengue. *Nature*. 2013;496: 504–507.
- 607 2. Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in Effectiveness or
608 Evidence?: Systematic Review and Meta-analysis. *PLoS Negl Trop Dis*. 2016;10:
609 e0004551.
- 610 3. Morrison AC, Zielinski-Gutierrez E, Scott TW, Rosenberg R. Defining challenges and
611 proposing solutions for control of the virus vector *Aedes aegypti*. *PLoS Med*. 2008;5: e68.
- 612 4. Ferguson NM, Kien DTH, Clapham H, Aguas R, Trung VT, Chau TNB, et al. Modeling the
613 impact on virus transmission of Wolbachia-mediated blocking of dengue virus infection of
614 *Aedes aegypti*. *Sci Transl Med*. 2015;7: 279ra37.
- 615 5. Anders KL, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Andari B, et al. The AWED
616 trial (Applying Wolbachia to Eliminate Dengue) to assess the efficacy of Wolbachia-infected
617 mosquito deployments to reduce dengue incidence in Yogyakarta, Indonesia: study
618 protocol for a cluster randomised controlled trial. *Trials*. 2018. doi:10.1186/s13063-018-
619 2670-z
- 620 6. Anders KL, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Andari B, et al. Update to the
621 AWED (Applying Wolbachia to Eliminate Dengue) trial study protocol: a cluster randomised
622 controlled trial in Yogyakarta, Indonesia. *Trials*. 2020. doi:10.1186/s13063-020-04367-2
- 623 7. Utarini A, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Ansari MR, et al. Efficacy of
624 Wolbachia-infected mosquito deployments for the control of dengue. *N Engl J Med*.
625 2021;384: 2177–2186.
- 626 8. Reiner RC, Achee N, Barrera R, Burkot TR, Chadee DD, Devine GJ, et al. Quantifying the
627 Epidemiological Impact of Vector Control on Dengue. *PLOS Neglected Tropical Diseases*.
628 2016. p. e0004588. doi:10.1371/journal.pntd.0004588
- 629 9. Stoddard ST, Morrison AC, Vazquez-Prokopec GM, Paz Soldan V, Kochel TJ, Kitron U, et
630 al. The role of human movement in the transmission of vector-borne pathogens. *PLoS Negl
631 Trop Dis*. 2009;3: e481.
- 632 10. Kraemer MUG, Bisanzio D, Reiner RC, Zakar R, Hawkins JB, Freifeld CC, et al. Inferences
633 about spatiotemporal variation in dengue virus transmission are sensitive to assumptions
634 about human mobility: a case study using geolocated tweets from Lahore, Pakistan. *EPJ
635 Data Sci*. 2018;7: 16.
- 636 11. Penny MA, Galactionova K, Tarantino M, Tanner M, Smith TA. The public health impact of
637 malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18
638 month follow-up Phase III data and simulation models. *BMC Med*. 2015;13: 170.
- 639 12. Penny MA, Verity R, Bever CA, Sauboin C, Galactionova K, Flasche S, et al. Public health
640 impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic
641 comparison of predictions from four mathematical models. *Lancet*. 2016;387: 367–375.

62

31

63

- 642 13. Slater HC, Foy BD, Kobylinski K, Chaccour C, Watson OJ, Hellewell J, et al. Ivermectin as
643 a novel complementary malaria control tool to reduce incidence and prevalence: a
644 modelling study. *Lancet Infect Dis.* 2020;20: 498–508.
- 645 14. Achee NL, Gould F, Perkins TA, Reiner RC Jr, Morrison AC, Ritchie SA, et al. A critical
646 assessment of vector control for dengue prevention. *PLoS Negl Trop Dis.* 2015;9:
647 e0003655.
- 648 15. Miller JC. A note on the derivation of epidemic final sizes. *Bull Math Biol.* 2012;74: 2125–
649 2141.
- 650 16. Multerer L, Glass TR, Vanobberghen F, Smith T. Analysis of contamination in cluster
651 randomized trials of malaria interventions. *Trials.* 2021;22: 613.
- 652 17. Multerer L, Vanobberghen F, Glass TR, Hiscox A, Lindsay SW, Takken W, et al. Estimating
653 intervention effectiveness in trials of malaria interventions with contamination. *Malar J.*
654 2021;20: 413.
- 655 18. Hawley WA, Terlouw DJ, Ter Kuile FO, Gimnig JE, Phillips-Howard PA, Hightower AW, et
656 al. Community-wide effects of permethrin-treated bed nets on child mortality and malaria
657 morbidity in western Kenya. *Am J Trop Med Hyg.* 2003;68: 121–127.
- 658 19. Hayes RJ, Moulton LH. *Cluster Randomised Trials.* CRC Press; 2017.
- 659 20. McCann RS, van den Berg H, Takken W, Chetwynd AG, Giorgi E, Terlouw DJ, et al.
660 Reducing contamination risk in cluster-randomized infectious disease-intervention trials. *Int*
661 *J Epidemiol.* 2018;47: 2015–2024.
- 662 21. Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, et al. Simulations
663 for designing and interpreting intervention trials in infectious diseases. *BMC Med.* 2017;15:
664 223.
- 665 22. Britton T. *Stochastic epidemic models: a survey.* *Math Biosci.* 2010;225: 24–35.
- 666 23. Cavany SM, Huber JH, Wieler A, Elliott M, Tran QM, España G, et al. Ignoring transmission
667 dynamics leads to underestimation of the impact of a novel intervention against mosquito-
668 borne disease. *medRxiv.* 2021; 2021.11.19.21266602.
- 669 24. Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, et al. Efficacy and risk of
670 harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a
671 cluster-randomised trial. *Lancet.* 2019;393: 1517–1526.
- 672 25. James S, Collins FH, Welkhoff PA, Emerson C, Godfray HCJ, Gottlieb M, et al. Pathway to
673 Deployment of Gene Drive Mosquitoes as a Potential Biocontrol Tool for Elimination of
674 Malaria in Sub-Saharan Africa: Recommendations of a Scientific Working Group. *Am J*
675 *Trop Med Hyg.* 2018;98: 1–49.
- 676 26. United Nations Publications. *World Population Prospects 2019: Demographic Profiles.*
677 2020.
- 678 27. Burattini MN, Chen M, Chow A, Coutinho FAB, Goh KT, Lopez LF, et al. Modelling the
679 control strategies against dengue in Singapore. *Epidemiol Infect.* 2008;136: 309–319.

64

32


65

- 680 28. Reich NG, Shrestha S, King AA, Rohani P, Lessler J, Kalayanarooj S, et al. Interactions
681 between serotypes of dengue highlight epidemiological impact of cross-immunity. *J R Soc*
682 *Interface*. 2013;10: 20130414.
- 683 29. Indriani C, Ahmad RA, Wiratama BS, Arguni E, Supriyati E, Tedjo Sasmono R, et al.
684 Baseline Characterization of Dengue Epidemiology in Yogyakarta City, Indonesia, before a
685 Randomized Controlled Trial of Wolbachia for Arboviral Disease Control. *The American*
686 *Journal of Tropical Medicine and Hygiene*. 2018. pp. 1299–1307. doi:10.4269/ajtmh.18-
687 0315
- 688 30. Kot M, Lewis MA, van den Driessche P. Dispersal data and the spread of invading
689 organisms. *Ecology*. 1996;77: 2027–2042.
- 690 31. Ten Bosch QA, Clapham HE, Lambrechts L, Duong V, Buchy P, Althouse BM, et al.
691 Contributions from the silent majority dominate dengue virus transmission. *PLoS Pathog*.
692 2018;14: e1006965.
- 693 32. United Nations Publications. *World Population Prospects 2019: Demographic Profiles*.
694 2020.

695


67

696 **Supplementary Figures**



697 **Fig. S7: Infection attack rates for each of the six models, delineated by control and**
698 **intervention arms.**
699

69



700

701

702

703

704


705

Fig. S8: The total bias introduced by each of the three biases. These biases are calculated by subtracting the efficacy of a model with that bias from a model without it, and as biases appear in multiple models there are three possible ways to quantify each bias. These different ways are shown with different line types. For transmission coupling and human movement, two of the ways are equivalent and so these are shown with a thicker line.

70

35

71



706 **Fig. S9: The contribution of each source of bias to the total bias.** Each panel shows a
 707 different way of calculating the contribution due to that source of bias, which is calculated as the
 708 difference in efficacy of a model without that bias and a model with that bias. This can be
 709 thought of as embedding the models, and subtracting adjacent pairs of models, so that the sum
 710 of each pair of models is equal to the total bias. The embeddings in each panel are: A: no
 711 bias → mosquito movement → human movement + mosquito movement → full model. B: no
 712 bias → human movement → human movement + mosquito movement → full model. C: no
 713

72

36

73

714 *bias* → *human movement* → *human movement + transmission coupling* → *full model*.
715



716

717

718

719

720

721

722

Fig. S10: Diagram of the checkerboard arrangement. Cell coloring refers to whether or not someone is the treatment or control cluster. In this case, the central cluster is an individual's home cluster. A_i describes the proportion of time someone spends in a cluster i clusters from their home cluster in one direction. A_iA_j is then the proportion of time someone spends in a cluster i clusters away in one direction, and j in the other.